The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets

Anti-Cancer Drug Design

Volumn 12, Issue 7, 1997, Pages 533-541

  Monks, A ^a   Scudiero, D A ^a   Johnson, G S ^b   Paull, K D ^b   Sausville, E A ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CYTARABINE; DEPSIPEPTIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; FLAVOPIRIDOL; FR 901228; MITOMYCIN C; PACLITAXEL; PROTEIN KINASE INHIBITOR; QUINOCARMYCIN; QUINOCARMYCIN CITRATE; SPICAMYCIN DERIVATIVE; UNCLASSIFIED DRUG; ZORUBICIN;

ANIMAL MODEL; CANCER; CANCER CELL CULTURE; CANCER MODEL; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES;

ANIMALIA;

EID: 0030832842     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. ALVAREZ, M , PAULL, K , MONKS, A , HOSE, C , LEE, J-S , WEINSTEIN, J., GREVER. M , BATES, S & FOJO, T (1995). Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. Journal of Clinical Investigation, 95, 2205.
2. BAI, R.L., PAULL, K.D., HERALD, C.L , MALSPEIS, L., PETTIT, G R & HAMEL, E. (1991) Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytoxicity data. Journal of Biochemistry, 266, 15882.
3. BURGER, A , KAUR, G., HOLLINGSHEAD, M , FISCHER, R., NAGASHIMA, K., MALSPEIS, L , DUNCAN, K & SAUSVILLE, E. (1997). Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5 500 with altered glycoprotein expression in vitro. Clinical Cancer Research, 3, 455,
4. CLEVELAND, E.S., MONKS, A , VAIGRO-WOLFF A., ZAHAREVITZ, D.W., PAULL, K , ARDALAN, K., COONEY, D.A. & FORD, H., JR (1995) Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the COMPARE program. Biochemical Pharmacology, 49, 947.
5. FINLAY, G J, MARSHALL, E, MATTHEWS, J H., PAULL, K.D. & BAGULEY, B.D. (1993). In Vitro assessment of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemotherapy Pharmacology, 31, 401.
6. FITZSIMMONS, S , WORKMAN, P., GREVER, M., PAULL, K., CAMALIER, R., & LEWIS, A (1996). Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. Journal of the National Cancer Institute, 88, 259.
7. FREIJE, J., LAWRENCE, J., HOLLINGSHEAD, M., DE LA ROSA, A., NARAYANAN, V., GREVER, M., SAUSVILLE, E , PAULL, K. & STEEG, P. (1997). Identification of compounds with preferential inhibitory activity against low-Nm-23-expressing human breast carcinoma and melanoma cell lines. Nature Medicine, 3, 395.
8. JAYARAM, H N , GHAREHBAGHI, K., RIESER, J., KROHN, K. & PAULL, K.D. (1992). Cytoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells. Biochemical and Biophysical Research Communications, 186, 1600.
9. KOO, H-M , MONKS, A., MIKHEEV, A., RUBINSTEIN, L., GRAY-GOODRICH, M., MCWILLIAMS, M.J., ALVORD, W.G , OIE, H., GAZDAR, A., PAULL, K , ZARBI, H. & VAN DE WOUDE, G (1996). Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Research, 56, 5211.
10. LEE, J-S., PAULL, K., ALVAREZ, M , HOSE, C., MONKS, A., GREVER, M , FOJO, T & BATES, S. (1994). Rhodamine efflux patterns predict p -glycoprotein substrates in the National Cancer Institute drug screen. Molecular Pharmacology, 46, 627.
11. LETEURTRE, F., KOHLHAGEN, G., PAULL, K.D. & POMMIER, Y (1994). Topoisomerase II inhibition and cytoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. Journal of the National Cancer Institute, 86, 1239.
12. MONKS, A., SCUDIERO, D., SKEHAN, P., SHOEMAKER, R , PAULL, K., VISTICA, D., HOSE, C., LANGLEY J., CRONISE, P., VAIGRO-WOLFF, A., GRAY-GOODRICH, M., CAMPBELL, H., MAYO, J. & BOYD, M.R (1991). Feasibility of a high-flux anticancer drug screen utilizing a diverse panel of human tumor cell lines in culture. Journal of the National Cancer Institute, 83, 757.
13. NEUBAUER, A., DODGE, R.K., GEORGE, S.L., DAE,FR , SILVER, R.T., SCHIFFER, C.A , MAYER, R.J., BALL, E D., WURSTER-HILL, D., BLOOMFIELD, C.D. & LIU, E.T. (1994). Prognostic importance in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood, 83, 1603.
14. PAULL, K.D., SHOEMAKER, R H , HODES, L., MONKS, A., SCUDIERO, D A., RUBINSTEIN, L., PLOWMAN, J & BOYD, M.R. (1989). Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development mean graph and COMPARE algorithm. Journal of the National Cancer Institute, 81, 1088.
15. PAULL, K D., LIN, C.M., MALSPEIS, L. & HAMEL, E. (1992). Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Research, 52, 3982.
16. PAULL, K D , HAMEL, E. & MAISPEIS, L. (1995). Prediction of biochemical mechanisms of action from the in vitro antitumor screen of the National Cancer Institute. In Cancer Chemotherapeutic Agents. Foye, W. (ed.), p. 9. ACS Professional Reference Book, ACS: Washington, DC.
17. PETERS, A , SMYTHE, A., WU, L., MONKS, A , BOYD, M & SHOEMAKER, R. (1994). Levels of mRNA coding for DNA topoisomerase II isoforms do not correlate with in vitro drug sensitivity. Oncology Reports, 1, 907.
18. SEDLACEK, H , CZECH, J., NAIK, R., KAUR, G , WORLAND, P., LOSIEWICZ, M., PARKER, B., CARLSON, B , SMITH, A , SENDEROWITZ, A & SAUSVILLE, E. (1996). Flavopiridol (L86 8275: NSC 649890), a new kinase inhibitor for tumor therapy. International Journal of Oncology, 9, 1143.
19. SEYNAEVE, C , KAZANIETZ, M., BLUMBERG, P. SAUSVILLE, E & WORLAND, P (1994). Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Molecular Pharmacology, 45, 1207.
20. TEW, K , MONKS, A., BARONE, L., ROSSER, D., AKERMAN, G., MONTALI, J , WHEATLEY, J. & SCHMIDT, D (1996). Glutathione associated enzymes in the human cell lines of the National Cancer Institute drug screening program. Molecular Pharmacology, 50, 149.
21. WEINSTEIN, J., KOHN, K., GREVER, M., VISWANADHAM, V., RUBINSTEIN, L., MONKS, A , SCUDIERO, D , WELCH, L., KOUTSOUKOS, A , CHIAUSA, A. & PAULL, K. (1992). Neural computing in cancer drug development: predicting mechanism of action. Science, 258, 447.
22. WEINSTEIN, J., MYERS, T., O'CONNOR, P , FRIEND, S , FORNACE, A , KOHN, K., FOJO, T , BATES, S , RUBINSTEIN, L , ANDERSON, N.L., BUOLAMWINI, J , VAN OSDOL, W., MONKS, A , SCUDIERO, D , SAUSVILLE, E., ZAHAREVITZ, D , BUNOW, B , VISWANADHAN, V., JOHNSON, G., WITTE, R &. PAULL, K (1997). An information-intensive approach to the molecular pharmacology of cancer. Science, 275, 343.
23. WOO, E , MONKS, A , WATKINS, S , WANG, A. & LAZO, J (1997). Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel. Cancer Chemical Pharmacology, in press.
24. WOSIKOWSKI, K , SCHUURHUIS, D., JOHNSON, K., PAULL, K., MYERS, T., WEINSTEIN, J. & BATES, S. (1997). Use of EGF receptor, c-erbB2 and TGFα gene expression profiles in the National Cancer Institute anticancer drug screen to identify EGF receptor and c-erbB2 pathway inhibitors. Journal of the National Cancer Institute, in press.
25. WU, L., SMYTHE, A M., STINSON, S.F , MULLENDORE, L.A., MONKS, A , SCUDIERO, D.A., PAULL, K.D., KOUTSOUKOS, A.D., RUBINSTEIN, L.V., BOYD, M.R. & SHOEMAKER, R.H. (1992). Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Research, 52, 3029.
26. ZUBROD, C., SCHEPARTZ, S., J. LEITER, K.M., ENDICOTT, L M & BAKER, C.G. (1966). The chemotherapy program of the National Cancer Institute: history, analysis and plans. Cancer Chemotherapy Reports, 50, 349.